Literature DB >> 23319187

Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.

Michael Karsy1, Marshall Gelbman, Paarth Shah, Odessa Balumbu, Fred Moy, Erol Arslan.   

Abstract

Since the recent publication of the World Health Organization brain tumour classification guidelines in 2007, a significant expansion in the molecular understanding of glioblastoma multiforme (GBM) and its pathological as well as genomic variants has been evident. The purpose of this review article is to evaluate the histopathological, molecular and clinical features surrounding emerging and currently established GBM variants. The tumours discussed include classic glioblastoma multiforme and its four genomic variants, proneural, neural, mesenchymal, classical, as well as gliosarcoma (GS), and giant cell GBM (gcGBM). Furthermore, the emerging variants include fibrillary/epithelial GBM, small cell astrocytoma (SCA), GBM with oligodendroglial component (GBMO), GBM with primitive neuroectodermal features (GBM-PNET), gemistocytic astrocytoma (GA), granular cell astrocytoma (GCA), and paediatric high-grade glioma (HGG) as well as diffuse intrinsic pontine glioma (DIPG). Better understanding of the heterogeneous nature of GBM may provide improved treatment paradigms, prognostic classification, and approaches towards molecularly targeted treatments.

Entities:  

Mesh:

Year:  2012        PMID: 23319187     DOI: 10.5114/fn.2012.32361

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  32 in total

1.  Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.

Authors:  Gisela Natalia Castro; Niubys Cayado-Gutiérrez; Felipe Carlos Martín Zoppino; Mariel Andrea Fanelli; Fernando Darío Cuello-Carrión; Mayra Sottile; Silvina Beatriz Nadin; Daniel Ramón Ciocca
Journal:  Cell Stress Chaperones       Date:  2014-08-26       Impact factor: 3.667

Review 2.  Therapeutic management of gliosarcoma in the temozolomide era.

Authors:  Mary Frances McAleer; Paul D Brown
Journal:  CNS Oncol       Date:  2015-04-23

3.  Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.

Authors:  J Castelli; L Feuvret; Q C Haoming; J Biau; E Jouglar; A Berger; G Truc; F Llamas Gutierrez; X Morandi; P J Le Reste; F Thillays; D Loussouarn; E Nouhaud; G Crehange; D Antoni; E Vauleon; R de Crevoisier; G Noel
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

4.  Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor.

Authors:  Audrey Bouchet; Marie Bidart; Imen Miladi; Céline Le Clec'h; Raphaël Serduc; Charles Coutton; Pierrick Regnard; Enam Khalil; Sandrine Dufort; Benjamin Lemasson; Jean Laissue; Laurent Pelletier; Géraldine Le Duc
Journal:  Tumour Biol       Date:  2014-03-16

5.  Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.

Authors:  Petr Busek; Eva Balaziova; Ivana Matrasova; Marek Hilser; Robert Tomas; Martin Syrucek; Zuzana Zemanova; Evzen Krepela; Jaromir Belacek; Aleksi Sedo
Journal:  Tumour Biol       Date:  2016-08-04

6.  Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?

Authors:  Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee
Journal:  Neurochem Res       Date:  2019-04-25       Impact factor: 3.996

7.  Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Jacob J Mandel; Adriana Olar; Matthew D Cykowski; Terri S Armstrong; Gregory N Fuller; Mark R Gilbert; John F De Groot
Journal:  J Neurooncol       Date:  2015-09-09       Impact factor: 4.130

Review 8.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

9.  Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells.

Authors:  Dae-Hee Lee; Dong-Wook Kim; Chang-Hwa Jung; Yong J Lee; Daeho Park
Journal:  Toxicol Appl Pharmacol       Date:  2014-07-14       Impact factor: 4.219

10.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.